Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Sunrun Inc Q1 2026 Earnings Call - Direct Sales Ramp and Grid Infrastructure Play Accelerate Amid Industry Turmoil
Sunrun delivered a quarter of strategic acceleration, not just volume. The company added nearly 19,000 customers in Q1 2026, driving storage attachment rates to 73% and pushing contracted net value cr...
- Added nearly 19,000 customers in Q1 2026, with average system sizes up 5% and a 73% storage attachment rate, up 2 points from Q4.
- Contracted net value creation came in at $108 million, near the high end of the guided range of $25 million to $125 million, signaling strong unit economics.
- Aggregate contracted subscriber value reached $980 million, with unit value up 14% year over year, driven by larger systems and higher storage penetration.
- +7 more takeaways
Digi International Inc. FQ2 2026 Earnings Call - ARR Surges 50% as Record Margins and Cash Flow Fuel Growth
Digi International delivered a record-breaking fiscal second quarter, driven by a 50% year-over-year surge in annualized recurring revenue (ARR) to $184 million and a 25% jump in revenue to $131 milli...
- Fiscal Q2 2026 revenue reached $131 million, a 25% year-over-year increase and a quarterly record.
- Annualized recurring revenue (ARR) surged 50% year-over-year to $184 million, reflecting a successful shift toward subscription-based solutions.
- Gross margins hit an all-time high of 64%, up 190 basis points year-over-year, driven by favorable ARR mix and pricing discipline.
- +10 more takeaways
Arcutis Biotherapeutics Q1 2026 Earnings Call - ZORYVE Revenue Surges 65% Amid Record Cash Flow and Pediatric Expansion
Arcutis Biotherapeutics reported a sharp revenue jump in the first quarter of 2026, driven by relentless demand for ZORYVE and favorable shifts in payer contracting. Net product revenues climbed 65% y...
- Net product revenues reached $105.4 million, a 65% increase from Q1 2025, driven by rising patient demand and improved gross-to-net dynamics from formulary upgrades.
- ZORYVE captured 48% of new prescriptions within the branded nonsteroidal topical basket, outpacing competitors and signaling strong physician preference.
- Weekly prescription volumes stabilized around 21,000 per week after a seasonal and weather-impacted Q1, with Q2 showing a 13% month-over-month uptick.
- +7 more takeaways
Universal Technical Institute Q2 2026 Earnings Call - Demand Surges as AI Disrupts White-Collar Labor Markets
Universal Technical Institute reported a strong second quarter for fiscal 2026, with revenue rising nearly 7% to $221 million and new student starts jumping 14% year-over-year. Management reaffirmed i...
- Total new student starts increased 14% year-over-year, with the UTI division up 15% and Concorde up 13%, signaling durable demand across trades and healthcare.
- Revenue reached $221 million, up nearly 7% year-over-year, supported by scaling new campuses and program expansion.
- New campus execution is outpacing models, with the UTI San Antonio campus exceeding initial start projections by nearly 60%.
- +7 more takeaways
Alto Ingredients Q1 2026 Earnings Call - 45Z Credits and Export Premiums Drive Profitability
Alto Ingredients delivered a strong first quarter of 2026, turning a $12 million net loss in the prior year period into a $4 million net income. The turnaround was fueled by higher export sales, impro...
- Alto Ingredients reported Q1 2026 net income of $4 million ($0.05 per share), a stark reversal from the $12 million net loss in Q1 2025.
- Adjusted EBITDA surged to $4.7 million, up from negative $4.4 million in the prior year period, driven by higher export sales and improved crush margins.
- Consolidated net sales were $225 million, a 4% year-over-year decline in volume partially offset by a 4% increase in average sales price per gallon.
- +7 more takeaways
Biote Q1 2026 Earnings Call - Recall Headwinds Mask Strong Practitioner Pipeline and H2 Growth Outlook
Biote’s first quarter results were defined by a self-inflicted supply crisis. The company’s voluntary recall of certain bioidentical hormone pellets created a $1.7 million revenue hit and a $1.5 milli...
- Biote reported Q1 revenue of $44.9 million, an 8.3% decline from the prior year, driven by a 13.2% drop in procedure revenue to $31.3 million due to a voluntary product recall.
- The recall caused an estimated $1.7 million in lost revenue and approximately $1.5 million in incremental costs, including $1.1 million in gross margin compression.
- Gross profit margin fell to 68.9% from 74.3% in Q1 2025, primarily due to the recall costs and a shift toward lower-margin third-party suppliers while internal production scaled.
- +12 more takeaways
Velocity Financial Q1 2026 Earnings Call - Steady Growth and Strong Capital Position Drive Results
Velocity Financial delivered a solid first quarter of 2026, with core net income rising 30% year-over-year and a healthy net interest margin of 3.56%. The company continued its disciplined approach to...
- Core net income increased 30% year-over-year, reflecting strong profitability and operational efficiency.
- Net interest margin held steady at 3.56%, consistent with Q4 2025 and well above cost of funds.
- Portfolio grew 25.6% year-over-year to $6.8 billion in UPB, driven by disciplined origination volumes of $639 million.
- +7 more takeaways
The Honest Company Q1 2026 Earnings Call - Margin Expansion and Focus on Wipes and Personal Care Drive Growth
The Honest Company delivered a strong Q1 2026, reporting organic revenue growth of 3.9% and a record adjusted gross margin of 43.5%. The company's 'Powering Honest Growth' initiative is clearly workin...
- Organic revenue grew 3.9% in Q1 2026, demonstrating the effectiveness of the 'Powering Honest Growth' strategy to focus on right-to-win categories.
- Adjusted gross margin hit a record 43.5%, a 480 basis point year-over-year improvement, driven by favorable mix and supply chain efficiencies.
- Wipes consumption surged 8.3% overall, with flushable wipes growing over 200% and becoming the number 4 brand in the category.
- +7 more takeaways
DoorDash Q1 2026 Earnings Call - Agentic Commerce and Tech Re-platforming Drive End-to-End Dominance
DoorDash delivered a quarter of relentless execution, with record DashPass engagement, accelerating international growth, and a global tech re-platforming initiative that is already yielding velocity ...
- Record DashPass engagement and subscription growth, with member acquisition accelerating year-over-year across all geographies.
- Global tech re-platforming is on track, with production traffic live across DoorDash, Wolt, and Deliveroo; feature development velocity is already improving.
- Management dismissed fears of AI agents disintermediating DoorDash, citing historical precedent with Google and Amazon where top-of-funnel players failed to retain users due to inferior end-to-end experiences.
- +7 more takeaways
Noodles & Company Q1 2026 Earnings Call - Adjusted EBITDA Triples as Menu and Marketing Discipline Drive 9% Comp Growth
Noodles & Company delivered a sharp turn in profitability, with adjusted EBITDA more than tripling to $7.7 million in Q1 2026, driven by a 460 basis point expansion in restaurant contribution margins....
- Adjusted EBITDA more than tripled year-over-year to $7.7 million in Q1 2026, reflecting a significant turnaround in profitability.
- System-wide comp sales grew 9.1%, with company-operated restaurants up 9.4% and franchise locations up 8%.
- Restaurant contribution margins expanded by 460 basis points to 14.9%, driven by sales leverage, lower food waste, and disciplined discounting.
- +7 more takeaways